Bristol Myers Squibb (CELG-RI) EBT Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) EBT Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
7.64% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
79.52% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
88.09% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
29.81% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-43.56% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-15.40% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
25.67% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-20.34% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
5.36% |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
5.36% |
| Date | Value |
|---|
| Mar 31, 2026 |
5.36% |
| Dec 31, 2025 |
-7.53% |
| Sep 30, 2025 |
12.13% |
| Jun 30, 2025 |
-3.25% |
| Mar 31, 2025 |
20.76% |
| Dec 31, 2024 |
-54.50% |
| Sep 30, 2024 |
-8.07% |
| Jun 30, 2024 |
-6.09% |
| Mar 31, 2024 |
-87.12% |
| Dec 31, 2023 |
29.27% |
| Sep 30, 2023 |
-1.80% |
| Jun 30, 2023 |
4.54% |
| Mar 31, 2023 |
123.15% |
| Dec 31, 2022 |
154.12% |
| Sep 30, 2022 |
17.87% |
| Jun 30, 2022 |
3.31% |
| Mar 31, 2022 |
-5.18% |
| Dec 31, 2021 |
7.28% |
| Sep 30, 2021 |
-0.15% |
| Jun 30, 2021 |
44.29% |
